A pharmacovigilance analysis of nearly five million adverse-event reports concludes that liver injury after CAR T-cell therapy is predominantly early and linked to cytokine release syndrome, with an additional persistent signal noted for CRS-independent cases tied to idecabtagene vicleucel (ID: 16b79c3e853265e2). The study argues that CRS is a major driver for observed hepatic events across reported cases. The finding affects monitoring plans: liver labs and management may need to be integrated into CRS timing and response workflows. The idecabtagene vicleucel observation also suggests that some hepatic injury risk may require product- or mechanism-specific attention in prospective evaluations. As a safety study, it does not replace clinical causality work, but it offers a broad signal map for clinicians and pharmacovigilance teams.